T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 43
- By:
- Publication type:
- Article
Works matching IS 21644403 AND DT 2019 AND VI 9 AND IP 3
Results: 19
1
2
Atezolizumab/ Nab-Paclitaxel of No Benefit in PD-L1-Negative Triple-Negative Breast Cancer.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 40
- By:
- Publication type:
- Article
3
High Incidence of Adverse Events Linked to Significant Economic Burden in Patients with Chronic Lymphocytic Leukemia.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 7
- By:
- Publication type:
- Article
4
FDA Approves Second Indication for Keytruda in the Treatment of Melanoma.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 45
- Publication type:
- Article
5
FDA Approves Alimta plus Keytruda as First-Line Treatment for Metastatic NSCLC.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 45
- Publication type:
- Article
6
Imbruvica plus Gazyva Approved as First-line Treatment for CLL/SLL.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 44
- Publication type:
- Article
7
Cabometyx Now Indicated for Hepatocellular Carcinoma.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 44
- Publication type:
- Article
8
Hospital Readmissions for Venous Thromboembolism a Substantial Cost in Patients with Cancer.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 1
- By:
- Publication type:
- Article
9
Elotuzumab, Lenalidomide, and Dexamethasone Combination Demonstrates High Response Rate in High-Risk Smoldering Multiple Myeloma.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 36
- By:
- Publication type:
- Article
10
Daratumumab Enhances Remissions When Added to Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 38
- By:
- Publication type:
- Article
11
Next-Generation BTK Inhibitor Highly Active in Relapsed or Refractory Mantle-Cell Lymphoma.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 34
- By:
- Publication type:
- Article
12
Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 32
- By:
- Publication type:
- Article
13
Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 29
- Publication type:
- Article
14
Inpatient Costs for Children and Young Adults with Acute Lymphoblastic Leukemia Higher at Specialized Cancer Centers, but for a Good Reason?
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 28
- By:
- Publication type:
- Article
15
Oral Rigosertib plus Azacitidine Combination Shows Promising Results in High-Risk Myelodysplastic Syndromes.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 18
- By:
- Publication type:
- Article
16
Luspatercept, First-in-Class Erythroid Maturation Agent, Reduces Transfusions in Patients with Low-Risk Myelodysplastic Syndromes.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 17
- By:
- Publication type:
- Article
17
Immunotherapy Combination Extends Survival in Advanced Refractory Colorectal Cancer.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 14
- By:
- Publication type:
- Article
18
Tumor Metabolism-Altering Regimen Achieves Clinical Benefit in Metastatic Pancreatic Cancer.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 1
- By:
- Publication type:
- Article
19
Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 3, p. 1
- By:
- Publication type:
- Article